Venetoclax and Ibrutinib in Treating Patients With Chronic or Small Lymphocytic Leukemia
Status:
Active, not recruiting
Trial end date:
2024-07-01
Target enrollment:
Participant gender:
Summary
This phase II trial studies how well venetoclax and ibrutinib work in treating patients with
chronic or small lymphocytic leukemia. Venetoclax may stop the growth of cancer cells by
blocking Bcl-2, a protein needed for cancer cell survival. Ibrutinib may stop the growth of
cancer cells by blocking some of the enzymes needed for cell growth. Giving venetoclax and
ibrutinib may help control chronic or small lymphocytic leukemia.